{"brief_title": "Denosumab (AMG 162) in Bisphosphonate Naive Metastatic Breast Cancer", "brief_summary": "This study is to evaluate various doses and schedules for denosumab administration and characterize the safety profile in this indication.", "condition": ["Breast Cancer", "Metastases", "Bone Metastases in Subjects With Advanced Breast Cancer"], "intervention_type": ["Biological", "Drug"], "intervention_name": ["Denosumab", "IV Bisphosphonates"], "description": ["Denosumab administered by subcutaneous injection", "Commercially available intravenous (IV) bisphosphonates administered per package insert, included pamidronate, ibandronic acid, and zoledronic acid"], "arm_group_label": ["Denosumab 60 mg every 12 weeks", "Denosumab 120 mg every 4 weeks", "Denosumab 180 mg every 4 weeks", "Denosumab 180 mg every 12 weeks", "Denosumab 30 mg every 4 weeks", "IV bisphosphonates every 4 weeks"], "other_name": ["AMG 162"], "criteria": "Inclusion Criteria: - Histologically or cytologically confirmed breast adenocarcinoma - At least one bone metastasis", "gender": "Female", "minimum_age": "18 Years", "maximum_age": "N/A", "healthy_volunteers": "No", "keyword": "Cancer", "mesh_term": ["Breast Neoplasms", "Neoplasm Metastasis", "Neoplasms, Second Primary", "Bone Neoplasms", "Bone Marrow Diseases", "Denosumab", "Diphosphonates"], "id": "NCT00091832"}